Non-invasive diagnostics Saccadous offers a mobile, non-invasive platform that analyzes involuntary eye movements to diagnose and track neurological disorders, presenting a clear opportunity to partner with clinics, hospitals, and digital health platforms seeking objective biomarkers for Parkinson's disease and related movement disorders.

Cloud analytics edge The core intelligence lives in the cloud with near real time analytics and scalable API access, which can be leveraged to offer integrated analytics services, data pipelines, or white-labeled decision support within existing clinical or research workflows.

Strategic partnerships Past collaboration with Barrow Neurological Institute and licensing of IP from Dignity Health indicate a receptiveness to academic and health system partnerships, suggesting targeted outreach to research centers, TIIMs, and health networks for joint studies or deployment.

IP and acquisitions Acquisition of TBID and its IP signals an active growth and IP consolidation strategy, presenting sales angles around expanding diagnostics capabilities, cross-licensing opportunities, and bundled offerings with complementary neurodiagnostic technologies.

Market readiness Revenue is under one million with a lean team, implying an agile, early-stage product likely seeking channel partners, distributors, or system integrators to scale adoption within neurology clinics, research labs, and digital health platforms globally.